Is the MDS-UPDRS a good screening tool for detecting sleep problems and daytime sleepiness in Parkinson’s disease? by Horváth, Krisztina et al.
Research Article
Is the MDS-UPDRS a Good Screening Tool for Detecting Sleep
Problems and Daytime Sleepiness in Parkinson’s Disease?
Krisztina Horváth,1 Zsuzsanna Aschermann,2 Péter Ács,2 Edit Bosnyák,2 Gabriella Deli,2
Endre Pál,2 József Janszky,2,3 Béla Faludi,2 Ildikó Késmárki,4 Sámuel Komoly,2
Magdolna Bokor,5 Eszter Rigó,5 Júlia Lajtos,6 Péter Klivényi,7 György Dibó,7
László Vécsei,7,8 Annamária Takáts,9 Adrián Tóth,9 Piroska Imre,10 Ferenc Nagy,11
Mihály Herceg,11 Anita Kamondi,12 Eszter Hidasi,13 and Norbert Kovács2,3
1 Doctoral School of Clinical Neuroscience, University of Pe´cs, Re´t Utca 2, Pe´cs 7623, Hungary
2Department of Neurology, University of Pe´cs, Re´t Utca 2, Pe´cs 7633, Hungary
3MTA-PTE Clinical Neuroimaging Research Group, Re´t Utca 2, Pe´cs 7623, Hungary
4Unified Health Centers of the City of Pe´cs, Dr. Veress Endre Utca 2, Pe´cs 7633, Hungary
5 Department of Neurology, Nyiro˝ GyulaHospital-National Institute of Psychiatry and Addictology, De´vai Utca 15a, Budapest, Hungary
6Department of Neurology, Kene´zy Gyula Hospital, Barto´k Be´la Utca 2-26, Debrecen, Hungary
7Department of Neurology, University of Szeged, Semmelweis Utca 6, Szeged, Hungary
8MTA-SZTE Neuroscience Research Group, Semmelweis Utca 6, Szeged, Hungary
9Department of Neurology, Semmelweis University, Balassa Utca 6, Budapest, Hungary
10Department of Neurology, Csolnoky Ferenc Hospital, Ko´rha´z Utca 1, Veszpre´m, Hungary
11Department of Neurology, Kaposi Mo´r Hospital, Tallia´n Gyula Utca 20-32, Kaposva´r 7400, Hungary
12National Institute of Clinical Neuroscience, Amerikai Utca 57, Budapest, Hungary
13Department of Neurology, University of Debrecen, Mo´ricz Zsigmond Ko¨ru´t 22, Debrecen, Hungary
Correspondence should be addressed to Norbert Kova´cs; kovacsnorbert06@gmail.com
Received 14 August 2014; Accepted 15 October 2014; Published 17 November 2014
Academic Editor: Peter Hagell
Copyright © 2014 Krisztina Horva´th et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) has separate items for measuring
sleep problems (item 1.7) and daytime sleepiness (1.8).The aimof our studywas to evaluate the screening sensitivity and specificity of
these items to the PDSleep Scale 2nd version (PDSS-2) andEpworth Sleepiness Scale (ESS). In this nationwide, cross-sectional study
460 PD patients were enrolled. Spearman’s rank correlation coefficients were calculated between the individual items, domains,
and the total score of PDSS-2 and item 1.7 of MDS-UPDRS. Similarly, the items and the total score of ESS were contrasted to item
1.8 of MDS-UPDRS. After developing generalized ordinal logistic regression models, the transformed and observed scores were
compared by Lin’s Concordance Correlation Coefficient. Only item 3 difficulties staying asleep and the “disturbed sleep” domain of
PDSS-2 showedhigh correlationwith “sleep problems” item 1.7 of theMDS-UPDRS. Total score of PDSS-2 hadmoderate correlation
with this MDS-UPRDS item. The total score of ESS showed the strongest, but still moderate, correlation with “daytime sleepiness”
item 1.8 of MDS-UPDRS. As intended, the MDS-UPDRS serves as an effective screening tool for both sleep problems and daytime
sleepiness and identifies subjects whose disabilities need further investigation.
1. Introduction
Recently the nonmotor symptoms (NMS) of Parkinson’s
disease (PD) have been increasingly recognized as major
burden of quality of life [1, 2]. The recently published
Movement Disorder Society-sponsored Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) was developed to assess
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a wide variety of nonmotor symptoms with good scale
properties. However, there are only a few published studies
available contrasting the MDS-UPDRS to other validated
scales on NMS. One of the papers demonstrated that the
MDS-UPDRS Part I for nonmotor experiences of daily living
had a strong convergent validity to theNon-Motor Symptoms
Questionnaire with the exception of patients with the most
severeNMS [1].However, theNMSQuestionnaire is a general
scale and not an instrument specially designed for certain
aspects of PD. In another recently published paper, the indi-
vidual items of MDS-UPDRS Part I were validated against a
number of scales for assessing individual NMS. However, this
study included a relatively low number of patients (𝑛 = 94)
and utilized the sole means of correlation calculations [3].
Although this research confirmed that theMDS-UPDRS Part
I total score had a strong convergent validity with a composite
score of scales for the NMS of PD and the majority of items
of MDS-UPDRS Part I had at least moderate correlation
with the representative nonmotor scales, the methodology
applied was unable to confirm agreement and concordance.
In our opinion, Spearman’s correlation coefficient is an
inappropriate measure of reliability because the strength of
linear association, andnot agreement, ismeasured.Therefore,
it is possible to have a high degree of correlation even if
agreement is poor [4, 5]. Because one of the most important
questions in assessing the model validity is if the model-
predicted values are precise and accurate at the same time [6],
concordance correlation measurements should be utilized to
establish agreement (concordance) by two scales.
Sleep-related problems are one of themost important and
troublesome nonmotor aspects of PD. These problems are
certainly multidimensional. For example, sleep-disturbances
associated with PD might be equally due to troublesome
nighttime OFF symptoms and other issues not specific for
PD (e.g., microarousals caused by sleep apnea syndrome).
Similarly, daytime sleepiness in PD might also be caused by
PD-specific or nonspecific causes.
MDS-UPDRShas separate items formeasuring nighttime
sleep-related problems (item 1.7) and daytime sleepiness (1.8)
each ranging from 0 (not present) to 4 (severe) scores. The
aim of our study was to evaluate the relationship of these
items to the PD Sleep Scale 2nd version (PDSS-2) and the
Epworth Sleepiness Scale (ESS).
The Parkinson’s Disease Sleep Scale 2nd version is a vali-
dated scale to assess sleep problems in PD [7]. It is composed
of 15 items evaluating three domains. Each item has a 5-point
Likert-type scale ranging from 0 “never” to 4 “very often”
(except for item 1 which is reversed). Each domain consists of
clusters of five questions (motor symptoms at night: 4, 5, 6, 12,
and 13; PD symptoms at night: 7, 9–11, and 15; and disturbed
sleep: 1–3, 8, and 14) [7]. Symptoms on each domain can be
scored in the range of 0–20 points, higher scores meaning
more nocturnal disturbance. The sum of the three domains
gives the total score of PDSS-2 with the maximum value of
60 points.The threshold indicating sleep problems is 11 points
for the Hungarian version of PDSS-2 [8–10].
Epworth Sleepiness Scale is composed of 8 items inves-
tigating a single domain to assess daytime sleepiness. The
usefulness of ESS was demonstrated in PD by several studies
[11–14]. Each item is scaled from 0 “would never doze” to
3 “high chance to doze.” The total score of ESS is the sum
of all item scores (0–24 points), higher scores representing
more severe daytime sleepiness. The cutoff value indicating
daytime sleepiness in Hungarian PD patients is 5 points [8].
2. Materials and Methods
2.1. Patients. In this nationwide cross-sectional multicenter
study 460 patients fulfilling the UK Brain Bank criteria
for PD were enrolled. Each subject gave written consent
in accordance with the ethical approval of the National
Ethical Committee (184/2013. 14437/2013/EKU). Each patient
was examined by a neurologist specialized in movement
disorders. A portion of these patients (357/460) participated
in the program of cultural adaptation and validation of the
MDS-UPDRS into Hungarian. Data were summarized at
University of Pe´cs (by KH and NK). Subsequently, levodopa
equivalent dosage calculations were performed [15].
Patients were screened for the presence of dementia by
the means of the Hungarian validated versions of Mattis
Dementia Rating Scale [16] (MDRS, 𝑛 = 345 patients) and
the Montreal Cognitive Assessment [17] (MOCA, 𝑛 = 460
patients). Patients receiving scores ≤125 points on Mattis
test and/or scores ≤22 points on MOCA were considered as
having major neurocognitive disorders [16].
2.2. Obtained Rating Scales. Besides sociodemographic and
PD-historic data, the Hungarian validated versions of MDS-
UPDRS [18], PDSS-2 [8], and ESS [8, 19] were obtained.
Because data from these scales were categorical, nonparamet-
ric tests were applied. As being part of the MDS-UPDRS,
Hoehn-Yahr Scale was also used to detect the overall severity
of PD. For description, medians with interquartile range (IR,
25th–75th percentiles) were calculated.
2.3. Prevalence and Correlations. Because the score of 0 on
the items means symptom-free condition, the prevalence of
each item was based on the portion of subjects having the
score >0 point on that particular item.
For correlation, Spearman’s rank correlation coefficients
were calculated. For correlation coefficients, the values 0–
0.299 were indicative of weak correlation, 0.300–0.599 were
indicative of moderate correlation, and 0.600–1.000 were
considered as high association [20].
2.4. Regression Models and Lin’s Concordance Correlation.
To evaluate the relationship between the scales, models
of generalized ordinal logistic regression were built with
bootstrap replication. Becausemost regression algorithms are
very sample specific, their generalizability to other samples
is quite limited. We chose a generalized logistic regression
model with lasso regularization as this method allowed
for bootstrap cross validation. Using this option we could
generalize the results to samples outside the index sample.
To determine the relationship between the PDSS-2 and
the “sleep problems” item of MDS-UPDRS (1.7), generalized
ordinal logistic regressionwas applied. First, we converted the
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PDSS-2 scores to MDS-UPDRS item 1.7 by regression analy-
sis. Subsequently, Lin’s Concordance Correlation Coefficient
(LCCC) [21] was used to calculate the concordance between
the true MDS-UPDRS scores and those estimated from the
PDSS-2. The concordance was categorized by the value of
LCCC as acceptable (0.601–0.900) and good (0.901–1.000).
Similar approach was utilized to determine the relation-
ship between ESS and “daytime sleepiness” item of MDS-
UPDRS (1.8). Based on the obtained generalized ordinal
logistic regression model we converted the ESS scores to
MDS-UPDRS item 1.8 and subsequently LCCC were calcu-
lated between the true and estimatedMDS-UPDRS 1.8 values.
2.5. Receiver Operating Characteristic (ROC) Curve. In order
to analyze how efficiently the MDS-UPDRS differentiates
patients having sleep-related problems from thosewhodonot
have any sleep-related problems, we applied ROC analysis.
After categorization of patients into two groups based on their
total score on PDDS-2 (patients with sleep problems: total
PDSS-2 score ≥11 points and patients without sleep problems:
<11 points), we performed a second categorization based on
MDS-UPDRS item 1.7 score (patients with sleep problems:
>0 points, patients without sleep problems: 0 points). Sub-
sequently these two different categorization methods were
compared to obtain positive and negative predictive values,
specificity, and sensitivity.
Afterwards, we also evaluated how appropriately the
MDS-UPDRS 1.8 item identified patientswith daytime sleepi-
ness. Categorization based on the ESS scores (patients having
daytime sleepiness: total score ≥5 points versus those not
having daytime sleepiness, ESS <5 points) was compared to
that of MDS-UPDRS item 1.8.
2.6. Statistical Analysis. All statistical analyses were carried
out using IBM SPSS software package (version 21, SPSS
Inc., Chicago, USA). Statistical significance level was set
to 5%. Because the SPSS Suite did not have built-in func-
tions for calculating LCCC, the freely available syntax files
developed by Marta Garcia-Granero were utilized (available:
http://gjyp.nl/marta/, accessed at Jan 7, 2013). Positive and
negative predictive values were calculated by the utilization
of the syntax adapted from the IBM website (http://www-01
.ibm.com/support/docview.wss?uid=swg21483380).
3. Results
3.1. Demographic and PD-Related Clinical Data. The subject
population consisted of 460 PD patients. The clinical char-
acteristics are demonstrated in Table 1. The LED was 214mg
(14–324mg, median and 25th–75th percentiles).
3.2. Sleep Problems. Based on MDS-UPDRS item 1.7, 315
patients (68.4%) had sleep-related problems (prevalence,
score >0). Only 1.7% of patients had the total score of
0 on PDSS-2. According to the PDSS total score, 324
patients (70.4%) had sleep-related problems clinically (score
≥11 points). Item 8 had the highest prevalence on PDSS-
2 (nocturia: 91.0%), while the lowest was at item 7 (hal-
lucinations: 15.0%). Out of the three domains of PDSS-2,
the “disturbed sleep” had the highest prevalence (98.3%).
Prevalence, frequency, and median values of sleep-related
items are demonstrated in Table 2.
Eight items of PDSS-2 had poor correlation with the
“sleep problems” item ofMDS-UPDRS (6: distressing dreams
at night, 7: nighttime distressing hallucinations, 8: nocturia,
9: immobility at night, 11: nighttime muscle cramps in
extremities, 12: painful posturing in the morning, 13: tremor,
and 15: snoring or difficulties in breathing). Six items had
moderate correlation with item 1.7 of MDS-UPDRS (1: bad
sleep quality, 2: difficulties falling asleep, 4: restlessness of
extremities at night, 5: urge to move extremities, 10: pain
in extremities, and 14: tired and sleepy after waking in the
morning). Furthermore, the total score and two domains of
PDSS-2 (motor symptoms and PD symptoms at night) had
also moderate correlation coefficients. Only a single item (3:
difficulties staying asleep) and the “disturbed sleep” domain
of PDSS-2 had high correlation with the “sleep problems”
item of MDS-UPDRS (Table 2).
Generalized ordinal logistic regression model was devel-
oped for PDSS-2 items to estimate MDS-UPDRS item 1.7.
Only PDSS items 1, 2, 3, and 5 contributed significantly to
the model (Supplementary Table 1 in Supplementary Materi-
als available online at http://dx.doi.org/10.1155/2014/806169).
The details of the ordinal logistic regression model are
presented in Supplementary Table 2. The predicted MDS-
UPDRS 1.7 values were subsequently compared to the true
MDS-UPDRS 1.7 values by LCCC. The value of LCCC was
0.833 (95% confidence interval: 0.809–0.864) demonstrating
acceptable agreement between the PDSS-2 and the “sleep
problems” item of MDS-UPDRS.
Based on the ROC analysis, MDS-UPDRS item 1.7 can
differentiate between patients with and without sleep-related
problems measured by PDSS-2 reliably (positive predictive
value: 0.714 with the 95% CI of 0.633–0.794; negative predic-
tive value: 0.851 with the 95% CI of 0.809–0.887; sensitivity:
0.754 with the 95% CI of 0.672–0.831; and specificity: 0.827
with 95% CI: 0.783–0.866).
3.3. Daytime Sleepiness. Based on MDS-UPDRS item 1.8,
345 patients (75.0%) had problems with daytime sleepiness
(prevalence, score >0). Only 4.74% of patients had the total
score of 0 points on ESS. According to ESS total score, 312
patients (67.8%) clinically had daytime sleepiness (ESS score
≥5 points). None of the items of ESS showed high correlation
with MDS-UPDRS item 1.8. While items 1–4 had moderate
correlation, items 5–8 had only poor correlation.The highest
value of correlation coefficient was observed between the
total score of ESS and item 1.8 of MDS-UPDRS (0.494)
(Table 3).
Generalized ordinal logistic regression model was devel-
oped for ESS items to estimate MDS-UPDRS item 1.8. Only
ESS items 1, 2, 3, and 7 contributed significantly to the model
(Supplementary Table 3). The details of the ordinal logistic
regression model are presented in Supplementary Table 4.
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Table 1: Clinical characteristics of the study cohort.
Characteristics Mean/number Percentage
Age 65.6 ± 9.7
Disease-duration 8.3 ± 7.8
Education years 11.8 ± 3.2
Sex 293 males 63.7%
Fluctuation 236 51.3%
Dyskinesia 184 40.0%
Hoehn-Yahr stage I 31 6.7%
Hoehn-Yahr stage II 275 59.8%
Hoehn-Yahr stage III 115 25.0%
Hoehn-Yahr stage IV 28 6.1%
Hoehn-Yahr stage V 11 2.4%
Deep brain stimulation therapy 113 24.5%
Levodopa/carbidopa intestinal gel infusion therapy 10 2.2%
Levodopa 358 77.8%
Dopamine agonists 299 65.0%
Without medication 14 3.0%
Levodopa and dopamine agonist combination 118 25.7%
COMT-inhibition 208 45.2%
MAO-inhibition 108 23.5%
Anticholinergic therapy 10 2.2%
Presence of dementia 10 2.2%
Antipsychotic medication 8 1.74%
Sedative medication usage 25 5.43%
Presence of dementia was defined as having scores ≤125 points on Mattis Dementia Rating Scale and/or scores ≤22 points on Montreal Cognitive Assessment.
The predicted MDS-UPDRS 1.8 values were subsequently
compared to the true MDS-UPDRS 1.8 values by LCCC. The
value of LCCC was 0.638 (95% confidence interval: 0.561–
0.708) demonstrating acceptable agreement between ESS and
“daytime sleepiness” item of MDS-UPDRS.
Based on the ROC analysis, MDS-UPDRS item 1.8 can
differentiate between patients with and without daytime
sleepinessmeasured byESS reliably (positive predictive value:
0.617 with the 95% CI of 0.527–0.703; negative predictive
value: 0.777 with the 95% CI of 0.731–0.819; sensitivity: 0.580
with the 95% CI of 0.500–0.660; and specificity: 0.859 with
95% CI: 0.817–0.895).
4. Discussion
Our data supports that the PDSS-2 has a strong and con-
vergent validity to “sleep problems” item of MDS-UPDRS.
Several items of disturbed sleep domain (items 1–3) had the
best correlation withMDS-UPDRS item 1.7.This relationship
is not surprising, because the question of item 1.7 queries the
following: “Over the past week, have you had trouble going to
sleep at night or staying asleep through the night? Consider
how rested you felt after waking up in the morning.” The
possible answers in MDS-UPDRS emphasize the length of
staying asleep (1: easily able to get a full night sleep, 2: with
difficulties can achieve a full night sleep, 3: stay asleep more
than the half the night, and 4: less than half of the night).The
most concordant item (number 3) of PDSS-2 asks also about
difficulty staying asleep, and the other acceptably concordant
questions (1: bad sleep quality and 2: difficulties falling asleep)
also contribute to this “disturbed sleep” domain.
For daytime sleepiness, we found considerably smaller
correlation between the ESS and MDS-UPDRS item 1.8 than
Gallagher and coworkers did [3]. In their paper Spearman’s
correlation coefficient was 0.56 based on the sample of 94
patients while our 0.494 value was based on the analysis of
460 patients.The discrepancy might be due to the differences
in the sample size and other patient characteristics.Wemight
assume at least two reasons behind these low correlation
coefficients: MDS-UPDRS and ESS apply different time-
frame and severity measurements. Whereas ESS asks the
patient to base his/her answer referring to “recent times,”
the MDS-UPDRS assesses the usual function “over the past
week including today.” ESS evaluates how likely the patient
will doze off in different situations (e.g., sitting and reading,
being a passenger in a car, and sitting and talking to someone
else). This type of severity scale assesses the frequency
and likelihood to differentiate between scores 1–3. On the
contrary, the severity scale of MDS-UPDRS item 1.8 is based
not only on the frequency (e.g., 3: sometimes versus 4: often),
but also on the different types of conditions where the patient
would fall asleep (e.g., 2: being alone and relaxing; 3-4:
eating or talking to people). Despite these concerns, we found
acceptable agreement between the ESS items and the daytime
sleepiness item of MDS-UPDRS.
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The authors are aware of some limitations of the study.
Despite having a relatively large sample of patients, the
majority of the subjects hadmild tomoderate disease severity
(Hoehn-Yahr Scale: 1–3). To overcome this problem, we
utilized a generalized logistic regression model with lasso
regularization as this method allowed for bootstrap cross
validation. Using this option we could generalize the results
to samples outside the index sample.
5. Conclusions
Our data demonstrate that the MDS-UPDRS nonmotor
experiences of daily works as a good screening questionnaire
aimed at identifying areas of disability related to sleep
problems and daytime sleepiness. The scale itself registers
presence and severity of items but has an official APPENDIX
with recommended more specific scales to pursue areas in
more detail. As a screening tool, there are some aspects of
sleep and daytime sleepiness which are not covered by MDS-
UPDRS, but the presence of nonzero scores on these MDS-
UPDRS items allows for fruitful utilization of more specific
and detailed rating instruments. In our view, studies focusing
on the sleep-related problems in PD can begin with theMDS-
UPDRS to accurately identify the cohort with sleep problems,
and then this group can be studied with the PDDS-2 and ESS
serving to assess all major dimensions in greater detail.
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